Summary

On January 17, 2024, Belgium inaugurated its new Health Data Agency, a project approved a year earlier. The agency is designed to improve the accessibility and reusability of health data for secondary purposes. This enhancement of data availability will be executed in a manner that ensures both security and adherence to privacy regulations.

Data types Involved

The data encompasses a broad spectrum. Founding members of the ADS (Sciensano, INAMI, SPF Public Health, KCE, AFPMS) have established a framework to map out the extensive data sets targeted, which include health, diseases, medical equipment and products, health determinants, related activities, etc. According to an agency program manager, this data will inherently be public and anonymized.

Structure of the Repository

The platform, as it currently stands, is relatively straightforward. It lists a variety of accessible datasets, while the agency itself does not hold the data. The data is organized using the DCAT_AP format.

Role of the Health Data Agency

The agency acts as an intermediary, facilitating the interaction between those who reuse data and the entities that own it. It offers tools and legal advice to aid in data exchange. Moreover, the agency is responsible for verifying the identity and intentions of data reusers, aligning its operations with the guidelines set forth by the European Health Data Space.

Seamus Larroque

CDPO / CPIM / ISO 27005 Certified

Home

Discover our latest articles

View All Blog Posts
June 11, 2026
Events
Data Governance
Data Privacy Enforcement
Health Data Warehouse

Vendor GDPR in Clinical Trials: What the IQVIA CNIL Ruling Changes for Sponsors and Healthtech Companies

On 26 May 2026 the CNIL fined IQVIA Operations France EUR 5 million for failures in its two authorised health data warehouses, LRX and EMR. The decision exposes weaknesses in CRO data protection practice that have direct consequences for every pharmaceutical sponsor relying on a CRO to process patient, prescription or trial data. This article unpacks the four areas of failure, explains why pseudonymisation no longer offers the cover many sponsors assume, and sets out a practical oversight checklist for sponsor data controllers.

February 9, 2026
AI
Biotech & Healthtech
Regulations & Guidelines
Healthcare

EU AI Act for Healthcare: What Life Sciences Companies Need to Know before August 2026

EU AI Act 2026 healthcare enforcement requires immediate compliance to avoid penalties.

February 2, 2026
Healthtech
US Privacy Law
USA

Navigating US Regulatory Requirements for AI-Powered Medical Devices: A Comprehensive Guide to FDA, HIPAA, and IRB Compliance

US AI medical device compliance requires navigating FDA, HIPAA, IRBs, and consent waivers strategically.

FAQs

Our frequently questions

No items found.